ENDRA Life Sciences (NASDAQ:NDRA) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Valuation and Earnings
This table compares ENDRA Life Sciences and Masimo’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ENDRA Life Sciences||$350,000.00||41.11||-$5.37 million||N/A||N/A|
|Masimo||$798.11 million||7.51||$131.61 million||$2.45||46.19|
This table compares ENDRA Life Sciences and Masimo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ENDRA Life Sciences||N/A||-394.07%||-266.99%|
Institutional and Insider Ownership
5.8% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 82.1% of Masimo shares are owned by institutional investors. 12.7% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 12.6% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
ENDRA Life Sciences has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for ENDRA Life Sciences and Masimo, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ENDRA Life Sciences||0||0||0||0||N/A|
Masimo has a consensus price target of $119.80, indicating a potential upside of 5.87%. Given Masimo’s higher possible upside, analysts plainly believe Masimo is more favorable than ENDRA Life Sciences.
Masimo beats ENDRA Life Sciences on 9 of the 11 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound systems. It offers diagnostic imaging technologies, such as CT, MRI, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease or internal bleeding. It also offers the Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.